To require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People’s Republic of China for finished pharmaceutical products and active pharmaceutical ingredients.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People’s Republic of China for finished pharmaceutical products and active pharmaceutical ingredients., changes federal law or congressional policy affecting importers, exporters, and commercial firms. The main policy domain is Trade, Healthcare, Foreign Policy.
Who Benefits and How
importers, exporters, and commercial firms may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, importers, exporters, and commercial firms may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section idfb362dda73314101b37550d0220d1f6e: 1. Short title This Act may be cited as the Pharmaceutical Supply Chain Security Act.
- Section id0B7B48969848446C92848F667FF55A99: 2. Reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People's Republic of China Not later than 180 days after the...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People’s Republic of China for finished pharmaceutical products and active pharmaceutical ingredients., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Key Policy Areas
Trade, Healthcare, Foreign Policy
Primary Purpose
This bill, To require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People’s Republic of China for finished pharmaceutical products and active pharmaceutical ingredients., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Policy Domains
Whole bill
Identified Gains
- importers, exporters, and commercial firms
Identified Costs
- federal implementing agencies
- importers, exporters, and commercial firms
Legislative Progress
IntroducedMr. Lankford introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_commission"
- → The commission identified in the operative section
- "secretary_of_commerce"
- → Secretary of Commerce
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology